Independent directory Public ClinicalTrials.gov records United States
ClinicalTrials.gov record
Completed Phase 3 Interventional Results available

A Safety and Effectiveness Study of Telaprevir in Chronic, Genotype 1, Hepatitis C Patients That Failed Previous Standard Treatment

ClinicalTrials.gov ID: NCT00703118

Public ClinicalTrials.gov record NCT00703118. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced Jul 22, 2026, 2:37 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Randomized, Double-Blind, Placebo-Controlled, Phase III Trial of 2 Regimens of Telaprevir (With and Without Delayed Start) Combined With Pegylated Interferon Alfa-2a (Pegasys) and Ribavirin (Copegus) in Subjects With Chronic, Genotype 1, Hepatitis C Infection Who Failed Prior Standard Treatment

Study identification

NCT ID
NCT00703118
Recruitment status
Completed
Study type
Interventional
Phase
Phase 3
Lead sponsor
Tibotec BVBA
Industry
Enrollment
663 participants

Conditions and interventions

Interventions

  • Telaprevir Drug
  • Peg-IFN-alfa-2a Drug
  • Ribavirin Drug
  • Placebo Drug

Drug

Eligibility (public fields only)

Age range
18 Years to 70 Years
Sex
All
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Sep 30, 2008
Primary completion
Jun 30, 2010
Completion
Jun 30, 2010
Last update posted
Jan 21, 2014

2008 – 2010

United States locations

U.S. sites
31
U.S. states
19
U.S. cities
31
Facility City State ZIP Site status
Not listed Birmingham Alabama
Not listed Coronado California
Not listed La Jolla California
Not listed Los Angeles California
Not listed San Francisco California
Not listed Aurora Colorado
Not listed Bradenton Florida
Not listed Gainesville Florida
Not listed Miami Florida
Not listed Atlanta Georgia
Not listed Indianapolis Indiana
Not listed Baltimore Maryland
Not listed Boston Massachusetts
Not listed Worcester Massachusetts
Not listed Detroit Michigan
Not listed Plymouth Minnesota
Not listed Kansas City Missouri
Not listed Egg Harbor Twp New Jersey
Not listed Albuquerque New Mexico
Not listed Manhasset New York
Not listed New York New York
Not listed Chapel Hill North Carolina
Not listed Durham North Carolina
Not listed Philadelphia Pennsylvania
Not listed Columbia South Carolina
Not listed Dallas Texas
Not listed Houston Texas
Not listed San Antonio Texas
Not listed Falls Church Virginia
Not listed Norfolk Virginia
Not listed Richmond Virginia

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 60 non-U.S. sites.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT00703118, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Jan 21, 2014 · Synced Jul 22, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT00703118 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →